OR WAIT null SECS
February 01, 2019
Janssen and MeiraGTx will collaborate on the development and commercialization of gene therapies for treating inherited retinal diseases.
January 29, 2019
Merck & Co.’s V920 (rVSV-ZEBOV) vaccine is expected to pave the way for the development of vaccines for emerging infectious disease with unpredictable disease incidence or geography, according to data and analytics company, GlobalData.
This injection formulation of USP-grade leucovorin calcium is now available in the United States.
The US and pharmerging markets will drive growth in drug spending; number of approvals to increase.
January 25, 2019
The European Medicines Agency has recommended that no new patients should start treatment with Lartruvo (olaratumab).
TC BioPharm (TCB), developer of CAR-T immuno-oncology products, has completed its first allogenic Gamma Delta T (GDT) cell banks.
January 22, 2019
Company to focus on innovation, growth, and productivity with creation of new units.
The companies will embark on a multi-year research collaboration to develop in-vivo delivery modalities for CRISPR/Cas9 by leveraging ProBioGen’s existing technology and expertise.
The acquisition of biopharmaceutical company TESARO is expected to strengthen GSK’s oncology pipeline and commercial footprint.
January 18, 2019
Dublin, Ireland-based biopharmaceutical company Allergan will establish an R&D presence in Cambridge, MA.